Fujifilm Diosynth blueprints another $1.2B expansion at North Carolina plant where it aims to employ 1,400

As the contract manufacturing industry stands at a crossroads, certain CDMOs are prospering while other stalwarts are going the sell-off route or warding off political and economic threats to their businesses.

Thursday, Fujifilm Diosynth proved it’s firmly in the first camp as the company unveiled another massive expansion in the U.S.

Fujifilm is investing $1.2 billion more to soup up its end-to-end biomanufacturing facility in Holly Springs, North Carolina, bringing the total investment in the plant to more than $3.2 billion, the company said in a release.

Aside from adding large-scale production capacity, the project is expected to create 680 new jobs in Holly Springs, increasing the total number of positions at the site to 1,400 by 2031.

The move will help Fujifilm Diosynth harness the full potential of the antibody-drug market, including antibody-drug conjugates (ADCs) and bispecifics. The company expects the antibody market to grow 8% per year through 2030.

FiercePharma.com

Michael Randle

Michael Randle